Ireland's Pharma Sector Is Decoupling Growth from Energy Use - What the 2026 Data Shows
Natural Gas consumption is down 5% for BioPharmaChem Companies in Ireland
The BioPharmaChem Ireland Sustainability and Responsible Care Report 2026 was published earlier this year and the headline narrative is one worth paying attention to.
The sector has achieved a significant increase in industrial productivity while simultaneously holding, and in many cases decreasing, its core environmental impact factors. Pharmaceutical exports rose from €77.5 billion to €99.9 billion between 2023 and 2024, an increase of 29%. Employment in the sector has grown by 5.2% over three years. Yet across energy, emissions and water, the direction of travel is downward. That is decoupling in practice, and it does not happen by accident.
What the energy data shows
Total energy consumption across BPCI member companies fell by approximately 3% over the three year reporting period, following on from a 4% reduction in the previous period. That is a sustained downward trend, not a one-off result.
Within that overall reduction, the picture between electricity and gas is shifting in a way that reflects the direction of decarbonisation strategy across the sector. Electricity consumption is up 2% while natural gas consumption is down 5%. These diverging trends indicate that sites are actively switching away from gas-fired processes toward electricity as part of site-level decarbonisation plans. That fuel switching, when done alongside investment in renewable energy, has a significant impact on the carbon intensity of the energy being consumed.
The result of that combined effort is striking. Electricity-related CO2 is down 30% over the three year period. That reduction has been driven by a cleaner national grid, increased procurement of low-carbon electricity by member companies and, in a number of cases, significant on-site generation from wind and solar. It is one of the most meaningful single statistics in the report and it reflects years of investment in both infrastructure and procurement strategy.
VOC emissions are down 23%
Alongside the energy data, it is worth noting that VOC emissions across the sector are down 23% over the same three year period. This matters in the context of the strengthened Industrial Emissions Directive, which tightens performance requirements on combustion systems, solvent-using processes and fugitive emission controls. The reduction reflects improvements in solvent control, enhanced monitoring and a sustained focus on pollution prevention. It is also, in part, a product of better energy systems. More efficient combustion, better-controlled processes and improved site infrastructure all contribute to lower VOC outputs as well as lower energy bills.
The regulatory context
The BioPharmaChem sector is navigating what the report describes as an unprecedented convergence of legislative reforms. The recast Industrial Emissions Directive 2.0, REACH updates, the Corporate Sustainability Reporting Directive and a suite of EU water protection measures are all reshaping expectations at the same time.
On the energy and infrastructure side specifically, the sector's sustainability strategy identifies this as one of four priority pillars, with a focus on transitioning to low-carbon production through enhanced energy efficiency, renewable integration and sustainable site development. That is not aspirational language. It is the framework within which capital investment decisions are now being made across the sector.
Member companies have already invested over €150 million in cleaner technologies and upgraded site infrastructure over the past four years. That level of investment reflects a sector that understands the direction of regulation and is moving to get ahead of it rather than react to it.
More of a reliance on renewable energy for Pharmaceutical companies in Ireland
What this means for individual sites
The aggregate data in the report is encouraging. But behind those averages are individual sites at very different points in their energy and decarbonisation journey. Some have invested heavily in renewables, ISO 50001 certification and real-time energy monitoring. Others are still at the stage of understanding what their consumption actually looks like and where the biggest opportunities sit.
The experience of sites that have taken a structured approach is consistent. The starting point is always visibility. Understanding where energy is being consumed, how efficiently the key systems are running and what the baseline looks like is what makes everything that follows possible. Without that foundation, capital investment decisions are harder to justify, grant applications are harder to build and progress is harder to verify.
If you are running a pharmaceutical or biopharmaceutical manufacturing facility in Ireland, the BioPharmaChem report is a useful benchmark for where the sector is heading. If it is something you would find useful to explore for your own site, the team at Watt Footprint is happy to have that conversation.
